Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V. Green AK, et al. Among authors: troso sandoval t. Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print. Clin Cancer Res. 2024. PMID: 39561275
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: troso sandoval t. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M, Chui MH, Zhou Q, Iasonos A, Sarasohn D, Cohen S, Friedman C, Grisham R, Konner J, Kyi C, Rubinstein M, Troso-Sandoval T, Aghajanian C, Makker V. Lumish M, et al. Among authors: troso sandoval t. Gynecol Oncol. 2024 Mar;182:75-81. doi: 10.1016/j.ygyno.2023.12.028. Epub 2024 Jan 22. Gynecol Oncol. 2024. PMID: 38262242 Clinical Trial.
HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iaosonos A, Tessier-Cloutier B, Ross DS, Troso-Sandoval T, Reis-Filho JS, Abu-Rustum N, Zhang Y, Ellenson LH, Weigelt B, Makker V, Chui MH. Shen S, et al. Among authors: troso sandoval t. Mod Pathol. 2023 Nov;36(11):100299. doi: 10.1016/j.modpat.2023.100299. Epub 2023 Aug 7. Mod Pathol. 2023. PMID: 37558129 Free PMC article.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, Chi DS, O'Cearbhaill RE, Zivanovic O. Praiss AM, et al. Among authors: troso sandoval t. Gynecol Oncol. 2023 Apr;171:23-30. doi: 10.1016/j.ygyno.2023.02.003. Epub 2023 Feb 16. Gynecol Oncol. 2023. PMID: 36804618 Free PMC article. Clinical Trial.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. Rubinstein MM, et al. Among authors: troso sandoval t. Gynecol Oncol. 2023 Feb;169:64-69. doi: 10.1016/j.ygyno.2022.11.028. Epub 2022 Dec 10. Gynecol Oncol. 2023. PMID: 36512912 Free PMC article. Clinical Trial.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Walsh EM, et al. Among authors: troso sandoval t. Breast Cancer Res Treat. 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20. Breast Cancer Res Treat. 2022. PMID: 35986801 Free PMC article.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. Moore KN, et al. Among authors: troso sandoval ta. Clin Cancer Res. 2022 Jan 1;28(1):36-44. doi: 10.1158/1078-0432.CCR-21-0158. Epub 2021 Oct 13. Clin Cancer Res. 2022. PMID: 34645648
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Zivanovic O, et al. Among authors: troso sandoval t. J Clin Oncol. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21. J Clin Oncol. 2021. PMID: 34019431 Free PMC article. Clinical Trial.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Among authors: troso sandoval ta. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.
22 results